Health · Healthcare & Policy · 2 hrs ago
India proposes immediate licence suspensions for drugs that fail key tests
India’s health ministry has proposed immediately suspending licences for drugs that fail key tests.
The change would apply when government analysts find problems with a medicine’s strength, dissolution, impurities, related substances or sterility.
These proposed rules would update India’s Drugs Rules, 1945, which currently require regulators to issue a show-cause notice before suspending or cancelling a licence.
The ministry says that process can leave medicines in circulation after they have been declared not of standard quality.
A licence would remain suspended until the manufacturer investigates the cause and takes corrective steps that satisfy the licensing authority.
Regulators would need to verify those steps before restoring the licence, helping reduce risks to patients and make recalls easier.
The proposal would also send test results to national and state or union territory regulators, as well as the medicine’s manufacturer and marketer.
The government will consider public comments for 30 days, and the rules would take effect after final publication in the Official Gazette.
India has proposed immediately suspending manufacturing licences for drugs that fail specified government quality tests.
The tests cover assay, dissolution, related substances, impurities and sterility.
Under current rules, regulators issue a show-cause notice before suspending or cancelling a licence.
The proposed suspension would remain in place until the manufacturer completes corrective steps to the regulator’s satisfaction.
The government will consider comments on the draft within 30 days, and the rules would take effect after final publication in the Official Gazette.
- Who
- India’s health ministry has proposed the changes; drug manufacturers and regulators would be affected.
- What
- The proposal would allow immediate suspension of a drug’s manufacturing licence after specified quality-test failures.
- When
- The draft is dated October 28, 2026, and was published on Wednesday, November 5, according to Hindu BusinessLine.
- Where
- India.
- Why
- The ministry says the current process can leave substandard drugs in circulation while regulators act, posing potential public-health risks and making recalls more difficult.
This story does not have two clearly opposing sides.
The draft proposal was dated.
Hindu BusinessLine reported that the draft was published on Wednesday and said the government would consider comments submitted within 30 days.
- Quality tests
- Assay, dissolution, related substances, impurities and sterility
- Current process
- Regulators issue a show-cause notice before suspending or cancelling a licence
- Licence restoration
- Requires verified corrective and preventive action and root-cause analysis
- Comment period
- 30 days
- Effective date
- On final publication in the Official Gazette
3 sources
What people are saying
During this period, the concerned drug may continue to remain in circulation, posing potential risks to public health and making effective recall more challenging
These parameters are critical to determining the quality of medicines. The proposed provision aims to ensure that instances of non-compliance involving these specified parameters are met with prompt regulatory action, thereby minimising potential risks to patients